Biotronik launches implantable BioMonitor for monitoring arrhythmias
18 October 2012
Biotronik has announced the European market release of
BioMonitor, an implantable cardiac device designed for the highly
accurate and reliable monitoring and management of patients with atrial
fibrillation (AF) or unexplained syncope.
BioMonitor is a subcutaneous implantable leadless cardiac monitor
for the long-term continuous remote monitoring of patients with
arrhythmias such as AF, bradycardia, sudden rate drop, asystole and
As sensitivity and specificity are essential in the detection of
arrhythmias such as AF, Biotronik has developed ClearSense
Technology with a unique three-vector signal detection that produces
highly precise and reliable arrhythmia monitoring.
The ClearSense Technology records three ECG channels converting
them to one high quality ECG input signal to clearly distinguish on
a beat-to-beat basis between a genuine signal and other artifacts
such as myopotentials due to body muscle contractions. This
innovative technology allows for optimal arrhythmia detection
independent of the device’s implant orientation within the body and
provides a longevity of 6.4 years.
BioMonitor is equipped with Biotronik’s home monitoring system,
which provides daily remote data transfer without patient
interaction — leading to high patient compliance. Its traffic light
system streamlines monitoring by highlighting the most relevant
information and providing accurate data for physicians to monitor
and manage their patients effectively.
“Only long-term continuous monitoring with reliable arrhythmia
detection offers the type of vital information necessary for
physicians to make the right therapy decisions when managing
patients with AF or unexplained syncope,” commented Professor
Gerhard Hindricks, director of the Department of Electrophysiology
at the Leipzig University Heart Center in Germany.
Professor Hindricks together with Professor Wilhelm Haverkamp
(Deputy of the Department of Cardiology at Charité Campus Virchow,
Humboldt University Berlin), and Professor Dietmar Bänsch (Director
of Cardiology Department and Rhythmology at the Rostock University
Hospital) are the world’s first physicians to implant the BioMonitor
and take advantage of this new approach for monitoring AF in their
“Effective management of AF and unexplained syncope starts with
effective monitoring,” said Professor Haverkamp. “BioMonitor, with
its ClearSense technology, and BIOTRONIK Home Monitoring offer the
optimal combination of reliability and efficiency.”
“BioMonitor supports physicians in every step of arrhythmia
management, from diagnosis via monitoring to individualized therapy
offering high quality solutions that benefit both physicians and
patients,” explained Professor Bänsch.